Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.

Johansen NJ, Dejgaard TF, Lund A, Schlüntz C, Larsen EL, Poulsen HE, Goetze JP, Møller HJ, Vilsbøll T, Andersen HU, Knop FK

Diabetes, obesity & metabolism16 Jun 2020Cited by 10 (Europe PMC)

PMID32543021DOI10.1111/dom.14078PepBankPUB-32543021

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, exenatide reduced total fat mass versus placebo.
In plain wordsIn adults with type 1 diabetes, exenatide reduced total fat mass more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTotal fat mass
Study
n = 108
Comparator
Placebo
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Total fat mass difference
−2.6 kg
versus placebo
Source sentences
Summary
Exenatide changed total fat mass by -2.6 kg (95% confidence interval [CI] -3.6; -1.6; P < 0.0001) and lean body mass by -1.1 kg (95% CI -1.9; -0.4; P = 0.01) compared with placebo, as assessed by dual-energy X-ray absorptiometry.
2 context sentences(design, population, supporting numbers)
Summary · context
108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy
Summary · context
Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population.
Report a problemFND-3254302101
02HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, exenatide reduced lean body mass versus placebo.
In plain wordsIn adults with type 1 diabetes, exenatide reduced lean body mass more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseLean body mass
Study
n = 108
Comparator
Placebo
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Lean body mass difference
−1.1 kg
versus placebo
Source sentences
Summary
Exenatide changed total fat mass by -2.6 kg (95% confidence interval [CI] -3.6; -1.6; P < 0.0001) and lean body mass by -1.1 kg (95% CI -1.9; -0.4; P = 0.01) compared with placebo, as assessed by dual-energy X-ray absorptiometry.
2 context sentences(design, population, supporting numbers)
Summary · context
108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy
Summary · context
Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population.
Report a problemFND-3254302102
03HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, exenatide reduced fat mass similarly in central and peripheral regions.
In plain wordsIn adults with type 1 diabetes, exenatide reduced central and peripheral fat mass by similar amounts.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCentral and peripheral fat mass reductions
Study
n = 108
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Fat mass reductions were similar for central and peripheral fat mass.
2 context sentences(design, population, supporting numbers)
Summary · context
108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy
Summary · context
Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population.
Report a problemFND-3254302103
04HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, exenatide did not change interleukin-2 versus placebo.
In plain wordsIn adults with type 1 diabetes, interleukin-2 did not change with exenatide compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeInterleukin-2
Study
n = 108
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Exenatide did not change levels of interleukin-2 or -6; tumour necrosis factor-α; C-reactive protein; N-terminal prohormone of brain natriuretic peptide; or 8-oxo-7,8-dihydroguanosine (RNA oxidation marker) and 8-oxo-7,8-dihydro-2'-deoxyguanosine (DNA oxidation marker).
2 context sentences(design, population, supporting numbers)
Summary · context
108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy
Summary · context
Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population.
Report a problemFND-3254302104
05HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, exenatide did not change interleukin-6 versus placebo.
In plain wordsIn adults with type 1 diabetes, interleukin-6 did not change with exenatide compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeInterleukin-6
Study
n = 108
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Exenatide did not change levels of interleukin-2 or -6; tumour necrosis factor-α; C-reactive protein; N-terminal prohormone of brain natriuretic peptide; or 8-oxo-7,8-dihydroguanosine (RNA oxidation marker) and 8-oxo-7,8-dihydro-2'-deoxyguanosine (DNA oxidation marker).
2 context sentences(design, population, supporting numbers)
Summary · context
108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy
Summary · context
Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population.
Report a problemFND-3254302105
06HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, exenatide did not change tumour necrosis factor-alpha versus placebo.
In plain wordsIn adults with type 1 diabetes, this inflammatory marker did not change with exenatide compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeTumour necrosis factor-alpha
Study
n = 108
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Exenatide did not change levels of interleukin-2 or -6; tumour necrosis factor-α; C-reactive protein; N-terminal prohormone of brain natriuretic peptide; or 8-oxo-7,8-dihydroguanosine (RNA oxidation marker) and 8-oxo-7,8-dihydro-2'-deoxyguanosine (DNA oxidation marker).
2 context sentences(design, population, supporting numbers)
Summary · context
108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy
Summary · context
Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population.
Report a problemFND-3254302106
07HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, exenatide did not change C-reactive protein versus placebo.
In plain wordsIn adults with type 1 diabetes, C-reactive protein did not change with exenatide compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeC-reactive protein
Study
n = 108
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Exenatide did not change levels of interleukin-2 or -6; tumour necrosis factor-α; C-reactive protein; N-terminal prohormone of brain natriuretic peptide; or 8-oxo-7,8-dihydroguanosine (RNA oxidation marker) and 8-oxo-7,8-dihydro-2'-deoxyguanosine (DNA oxidation marker).
2 context sentences(design, population, supporting numbers)
Summary · context
108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy
Summary · context
Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population.
Report a problemFND-3254302107
08HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, exenatide did not change N-terminal prohormone of brain natriuretic peptide versus placebo.
In plain wordsIn adults with type 1 diabetes, this cardiac marker did not change with exenatide compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeN-terminal prohormone of brain natriuretic peptide
Study
n = 108
Comparator
Placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Exenatide did not change levels of interleukin-2 or -6; tumour necrosis factor-α; C-reactive protein; N-terminal prohormone of brain natriuretic peptide; or 8-oxo-7,8-dihydroguanosine (RNA oxidation marker) and 8-oxo-7,8-dihydro-2'-deoxyguanosine (DNA oxidation marker).
2 context sentences(design, population, supporting numbers)
Summary · context
108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy
Summary · context
Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population.
Report a problemFND-3254302108
09HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, exenatide did not change the RNA oxidation marker versus placebo.
In plain wordsIn adults with type 1 diabetes, the RNA oxidation marker did not change with exenatide compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeRNA oxidation marker
Study
n = 108
Comparator
Placebo
Analysis
Secondary
Outcome group
Oxidative stress · Whole body
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Exenatide did not change levels of interleukin-2 or -6; tumour necrosis factor-α; C-reactive protein; N-terminal prohormone of brain natriuretic peptide; or 8-oxo-7,8-dihydroguanosine (RNA oxidation marker) and 8-oxo-7,8-dihydro-2'-deoxyguanosine (DNA oxidation marker).
2 context sentences(design, population, supporting numbers)
Summary · context
108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy
Summary · context
Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population.
Report a problemFND-3254302109
10HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, exenatide did not change the DNA oxidation marker versus placebo.
In plain wordsIn adults with type 1 diabetes, the DNA oxidation marker did not change with exenatide compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeDNA oxidation marker
Study
n = 108
Comparator
Placebo
Analysis
Secondary
Outcome group
Oxidative stress · Whole body
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Exenatide did not change levels of interleukin-2 or -6; tumour necrosis factor-α; C-reactive protein; N-terminal prohormone of brain natriuretic peptide; or 8-oxo-7,8-dihydroguanosine (RNA oxidation marker) and 8-oxo-7,8-dihydro-2'-deoxyguanosine (DNA oxidation marker).
2 context sentences(design, population, supporting numbers)
Summary · context
108 individuals with type 1 diabetes aged ≥18 years on multiple daily injection therapy
Summary · context
Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population.
Report a problemFND-3254302110

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.